The vitamin D metabolite 24, 25[OH] 
Introduction
The vitamin D metabolite 24,25-[OH] 2 D 3 is generated from 25-hydroxyvitamin D 3 (25-OHD 3 ) and 1,25-dihydroxyvitamin D 3 (1, 2 D 3 ) by the activity of the cytochrome P450 24-hydroxylase (24A2) that is expressed in many tissues, including the liver (Chen et al. 1993) . Once produced in peripheral tissues, 24, 2 D 3 circulates in plasma and is taken up by the liver where it accumulates until it subjected to further hydroxylation and excretion in the bile and the feces. Though it was once thought to be inactive, studies during the past 20 years have shown that 24, 2 D 3 has biological activity, stimulating the resting zone chondrocytes and promoting the maturation of cartilage to bone (Dickson & Maher 1985 , Wientroub et al. 1987 , Miyahara et al. 1994 . Recently, our laboratory demonstrated that 24,25- [OH] 2 D 3 is a potent inhibitor of apo A-I synthesis and HDL secretion by hepatocytes (Wehmeier et al. 2011) . This suggests that this compound may have other unanticipated biologic effects that remain to be elucidated.
Many of the cellular effects of vitamin D are mediated by the vitamin D receptor (VDR), a member of the steroid hormone superfamily of nuclear receptors. After ligand binding, VDR and its partner retinoid x receptor (RXR) mediate the transcriptional effects of the hormone on target genes (Kimmel-Jehan et al. 1997) . However, recent studies have shown that vitamin D exhibits nongenomic signaling activity including activation of ion channels and activation of various mitogen-activated protein (MAP) kinases and pp60c-src (Chappel et al. 1997 , Gniadecki 1998 , Zhang et al. 2007 , Buitrago et al. 2013 . Unlike 1,25-[OH] 2 D 3 , which has high affinity for the VDR (Makin et al. 1989), 24,25-[OH] 2 D 3 binds the VDR poorly if at all (Uchida et al. 1997 ) but in resting zone chondrocytes and other cells, stimulates various intracellular protein kinases including pp60c-src, PKCα, and MAP kinase, and phospholipase A2 activity (van Leeuwen et al. 2001) . Since several of these proteins are involved in signaling pathways shown to mediate TNF α-related suppression of apo A-I expression (Haas et al. 2003 , Beers et al. 2006 , Parseghian et al. 2014 and since 24,25-[OH] 2 D 3 is a known and potent inhibitor of apo A-I synthesis (Wehmeier et al. 2011) , we investigated whether some of these pathways are modulated by 24, 2 D 3 in hepatocytes. The amount of 24,25-[OH] 2 D 3 required for repressing apo A-I gene expression (Wehmeier et al. 2011) was significantly lower than media concentrations required for the activation of various PPARs or the bile acid receptor farnesoid-X receptor (FXR) (Vu-Dac et al. 1998 , Sakamoto et al. 2000 , Claudel et al. 2002 
Materials and methods

Materials
Phorbol-12-myristate-13-acetate (PMA), gemfibrozil, and the vitamin D metabolite 24,25-[OH] 2 D 3 was purchased from Sigma Chemical Company. Immobilon-P for Western blotting was purchased from Millipore and enhanced chemiluminescence materials were purchased from Pierce Biotechnology. Thin layer chromatography plates and antibodies to PKCα and phosphorylated PKCα were obtained from Millipore. Antibodies to phosphorylated and unphosphorylated forms of P38 MAP kinase, JNK, ERK1/2, and c-jun were purchased from Cell Signaling, Inc., as was an antibody to β-actin. Antibodies specific for human apo A-I and albumin were purchased from Thermo Fisher Scientific. Control and c-jun-specific siRNA and antibodies to PPARα and RXRα were purchased from Santa Cruz Biotechnology. Secondary antibodies were purchased from Southern Biotech (Birmingham, AL, USA). 14 C-chloramphenicol was purchased from PerkinElmer and reagents for luciferase assays were purchased from Promega. Enzyme-linked immunosorbent assay (ELISA) kits (DuoSets) for measuring interleukin 1β (IL-1β), interleukin 2 (IL-2), interleukin 6 (IL-6), interleukin 8 (IL-8), and tumor necrosis factor α (TNF α) were purchased from R&D Systems. Lipopolysaccharide (E. coli O127:B8) (LPS) was purchased from Thermo Fisher Scientific. All other reagents were from Sigma Chemical Company or Thermo Fischer Scientific.
Western blotting
HepG2 cells were treated as described in each figure and protein samples were prepared by lysing the cells in buffer containing 50 mM tris(hydroxymethyl)aminomethane hydrochloride (Tris-Cl) (pH 7.4), 1% sodium dodecylsulfate (SDS), and 1 mM ethylenediaminetetraacetic acid (EDTA). For measurement of apo A-I and albumin levels, conditioned medium was obtained from the cells after 24-h of treatment. Protein content was measured using the bicinchoninic acid assay with a kit from Pierce Biotechnology. Fifty microgram of protein was fractionated by electrophoresis on a 10% SDS polyacrylamide gel and transferred to nitrocellulose as described (Towbin et al. 1979) . The nitrocellulose was blocked by shaking in 5% nonfat dry milk in phosphate-buffered saline (PBS) (50 mM sodium phosphate, 150 mM NaCl, pH 7.4) containing 0.05% Tween-20 for 2 h at room temperature, before addition of the primary antibody (diluted in 1% nonfat dry milk in PBS) diluted according to the manufacturer's recommendations, and incubated overnight at 4°C. After 4-5 min washes in PBS-T, the membranes were incubated with either a goat-anti-mouse or a goat-antirabbit secondary antibody (diluted 1:5000 in PBS). After 4-5 min washes, the binding was visualized by enhanced chemiluminescence and autoradiography. The signal for each band was quantified using NIH Image J software.
Transient transfection
Apo A-I promoter activity was measured in HepG2 cells transfected with pAI.474.CAT, which contains the apo A-I gene promoter fused to the chloramphenicol acetyltransferase (CAT) gene (Gorman et al. 1982) .
Collagenase promoter activity was measured in HepG2 cells transfected with phu.collase-73/+63-CAT, which contains the AP-1-responsive collagenase promoter fused to CAT (Mitchell & Cheung 1991) , while the plasmid pJ6 TK pG13, containing six copies of a PPARα response element driving luciferase expression, was obtained from Dr. Bart Staels (Institut Pasteur de Lille, Lille, France). The plasmid pCMV.SPORT.β-gal, which contains the β-galactosidase gene fused to the cytomegalovirus promoter, was used to normalize transfection efficiency (Herbomel et al. 1984) . Cells were transfected with 1 μg of each plasmid using Lipofectamine and 24 h later treated as indicated in each figure for 24 h.
Inhibition of c-jun expression via siRNA
HepG2 cells were transfected with either control or c-junspecific inhibitory RNA (siRNA) using lipofectamine in the presence of various plasmids as described below. Previous studies in our laboratory have shown that this methodology knocks down c-jun expression over 80% (Parseghian et al. 2014) .
Proinflammatory cytokine measurement by ELISA
IL-1β, IL-2, IL-6, IL-8, and TNF α levels were measured in 100 μL of conditioned medium from cells treated with solvent, 50 nM 24,25-[OH] 2 D 3 , 50 nM PMA, or 10 ng/mL LPS for 24-h. The immunoassays were performed essentially as described by the manufacturer's general ELISA protocol though two changes were incorporated. First, the samples and standards were allowed to bind the capture antibody by incubating the plates at 4°C overnight. Second, detection antibody binding was also at 4°C overnight. Optical densities at 450 nm (signal) and 570 nm (background) were measured with an ELx800 microplate spectrophotometer (BioTek Instruments) and exported to Microsoft Excel. Cytokine levels were calculated from the linear region of the standard curves using Microsoft Excel.
Statistics
Measurements are reported as the mean ± s.d. Analysis of variance (ANOVA) and the Students t-test for independent variables were performed with Statistica for Windows (Statsoft Inc, Tulsa, OK, USA). Statistical significance was defined as a two-tailed P < 0.05.
Results
The effect of 24,25-[OH] 2 D 3 on PPARα and RXRα expression
Previous studies suggested that 10-100 nM 24,25-[OH] 2 D 3 were sufficient to maximally suppress hepatic apo A-I gene expression (Wehmeier et al. 2011 , and 24 h and protein extracts were prepared as described above. PKCα activity, as assessed by phosphorylation on serine 3 ( Fig. 3A and B) , increased by 3.5-fold (P < 0.0001) at 1 h and this was essentially maintained throughout the 24 h. These results suggest that 24,25-[OH] 2 D 3 induces PKCα-mediated signaling in hepatocytes. JNK1 phosphorylation (C and D) increased 2.1-fold at 3 h (P < 0.0004 relative to phospho-JNK1 levels at time-zero) but decreased to control levels by 24 h. ERK1/2 phosphorylation (E and F) increased 1.8-fold at 3 h (P < 0.0006 relative to phospho-ERK1/2 levels at timezero) and decreased slightly from peak levels at 24 h. Phosphorylation of c-jun (G and H) reached a maximum at 1 h (2.9-fold) (P < 0.0005 relative to phospho-c-jun levels at time-zero) and was sustained at 24 h. Total PKCα, JNK1, ERK1/2, and c-jun levels did not change with 24, alone. N = 6; *P < 0.0008, P < 0.0007, and P < 0.0001, respectively, relative to control cells. We next determined if the c-jun component of AP1 was required for PMA and 24, 2 D 3 to induce collagenase promoter activity. HepG2 cells were transfected with the collagenase reporter plasmid in the presence of a control siRNA or a c-jun-specific siRNA. After 48-h, the cells were treated with 100 nM PMA or 50 nM 24,25-[OH] 2 D 3 for 24 h and CAT activity was measured (Fig. 4B) . In the presence of the control siRNA, PMA induced collagenase reporter gene expression 2.4-fold (P < 0.0001) and 24,25- 
The effect of 24,25-[OH] 2 D 3 on apo A-I promoter activity
HepG2 cells were transfected with the plasmid pAI.474. CAT and either a c-jun-specific siRNA or a control siRNA and treated with either 100 nM PMA or 50 nM 24,25-[OH] 2 D 3 for 24 h (Fig. 5) . In the presence of the control siRNA, treatment of HepG2 cells with PMA decreased apo A-I promoter activity by 41.2% (P < 0.002), while treatment with 24,25-[OH] 2 D 3 decreased apo A-I promoter activity by 38.7% (P < 0.002). However, in cells depleted of c-jun via siRNA-mediated knockdown, neither PMA nor 24,25-[OH] 2 D 3 suppressed apo A-I promoter activity significantly (only 5.9 and 7.7%, respectively, relative to control; both changes were not statistically significant). Furthermore, apo A-I promoter activity was significantly higher in cells transfected with the c-jun siRNA and treated with PMA relative to cells transfected with the which correlated with changes in c-jun phosphorylation (also 1 h). Phosphorylation of both JNK1 and ERK1/2 was elevated only at 3 h post-treatment. (B) N = 6; *P < 0.0001, P < 0.0001, P < 0.0001, and P < 0.0001 respectively, relative to time-zero. (D) N = 6; *P < 0.0004 and P < 0.001, respectively, relative to time-zero. (F) N = 6; *P < 0.0006, P < 0.0004, and P < 0.0002, respectively, relative to time-zero. (H) N = 6; *P < 0.0005, P < 0.0003, P < 0.0003, and P < 0.0001, respectively, relative to time-zero. 
The effect of 24,25-[OH] 2 D 3 on proinflammatory cytokine expression in HepG2 cells
HepG2 cells were treated as described in Materials and methods, and IL-1β (A), IL-2 (B), IL-6 (C), IL-8 (D), and TNF α levels were measured by ELISA and apo A-I and albumin levels were measured by Western blot of the conditioned medium (Fig. 6) (Genini & Catapano 2006 , Lefebvre et al. 2010 . PPARα is phosphorylated by PCKα in PMA-treated cells (Gray et al. 2005) , though this post-translational modification resulted in increased transcriptional activity. Likewise, ERK1/2 has been shown to phosphorylate PPARα in insulin-treated cells, also enhancing its transcriptional activity (Shalev et al. 1996) . In contrast, JNK1 has been shown to suppress PPARα activity in hepatocytes, though this effect was mediated by the corepressors nuclear corepressor 1 (NCoR1) and nuclear receptor interacting protein 1 (NRIP1), without changes in PPARα expression (Vernia et al. 2014) . Additional studies will be required to determine the mechanism. However, these results suggest that 24,25-[OH] 2 D 3 may suppress apo A-I gene expression in part by reducing the expression of these two key transcriptional regulators. It is noteworthy that proinflammatory cytokines including tumor necrosis factor α inhibit apo A-I gene expression by down-regulating the expression of various steroid hormone nuclear receptors including PPARα and RXRα (Beigneux et al. 2000 , Wang & Wan 2008 ). This effect is in part due to induction of ERK1/2 and JNK1 branches of the MAP kinase pathway, leading to the activation of c-jun and squelching of apo A-I promoter activity (Haas et al. 2003 , Beers et al. 2006 , Parseghian et al. 2014 rapidly stimulated (within 1 h) PKCα phosphorylation as well as c-jun phosphorylation, whereas JNK1 and ERK1/2 required longer (3 h) leading to the rapid activation of AP1 activity by stimulating serine 63 phosphorylation on c-jun (Davis 2000) . Furthermore, treatment with 24, 2 D 3 induced the AP1-responsive collagenase reporter gene expression to a similar extent as the phorbol ester PMA. However, this response was inhibited by the addition of a c-jun siRNA but not a control siRNA. Likewise, treatment with 24,25-[OH] 2 D 3 inhibited apo A-I promoter activity as did the phorbol ester PMA, to a similar extent, which was inhibited by the c-jun-specific siRNA but not the control siRNA. This data suggests that of the two potential pathways involved in suppressing apo A-I gene expression (nuclear receptor expression or AP1-dependent inhibition), AP1-dependent inhibition is the most likely pathway involved. If both pathways were involved, 24,25-[OH] 2 D 3 would inhibit apo A-I gene expression to a greater extent than observed with PMA treatment.
Finally, treatment with 24,25-[OH] 2 D 3 increased IL-1β, IL-6, and IL-8 levels in the conditioned medium, similar to (Petrasek et al. 2012) , hepatocytes, including HepG2 cells, also express the cytokine ( Palabiyik et al. 2016 , Zhang et al. 2016 . Once released, IL-1β has been shown to act in both autocrine and paracrine fashions to increase its own expression (Szabo & Petrasek 2015) as well as the expression of other proinflammatory cytokines, including TNF α (Mandrekar et al. 2011 ), though we did not observe the latter in our studies. IL-1β activates hepatic stellate cells leading to fibrosis (Miura et al. 2010) and increases triglyceride accumulation in hepatocytes (Miura et al. 2010 , Petrasek et al. 2012 . IL-6 is also expressed in HepG2 cells (Deng et al. 2014) and is important in promoting the acute phase response as well as liver regeneration and obesity and insulin resistance. IL-6 induces the expression of c-reactive protein, serum amyloid A, fibrinogen, and haptoglobin (Bode et al. 2012) , while IL-6 knockout mice have impaired liver regeneration (Cressman et al. 1996) . The effect of IL-6 on obesity and glucose metabolism is more complex. While IL-6 administration decreased insulin action in skeletal muscle and liver in hyperinsulinemiceuglycemic clamp studies (Kim et al. 2004 ), IL-6-deficient mice displayed hyperleptinemia and hyperinsulinemia, liver inflammation, and steatohepatitis (Wallenius et al. 2002 , Matthews et al. 2010 . Similar to IL-1β and IL-6, IL-8 is also expressed in HepG2 cells (Wang et al. 2016) . IL-8 is an angiogenic factor for human microvascular cells (Heidemann et al. 2003) and has chemoattractant and neutrophil-activating activity (Stillie et al. 2009 ). These results suggest that 24,25-[OH] 2 D 3 may enhance hepatic inflammation in part by stimulating IL-1β, IL-6, and IL-8 expression.
In conclusion, the results of our studies strongly suggest that the principle vitamin D metabolite 24,25-[OH] 2 D 3 has proinflammatory effects in HepG2 cells. Serum 24, 2 D 3 levels in healthy individuals has been reported to be 2.3 ng/mL (6.2 nM) (Tartarotti et al. 1984) , and though it can rapidly concentrate in vitamin D-responsive tissues as well as the liver, to our knowledge, there have been no studies examining tissue levels in humans; nor have there been studies examining how changes in physiological state may lead to changes in tissue levels. These aspects, as well as additional studies examining the molecular mechanism by which 24,25-[OH] 2 D 3 enhances inflammation remain for investigation both in vitro and in vivo.
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